يعرض 1 - 20 نتائج من 72 نتيجة بحث عن '"Antolín Novoa, Silvia"', وقت الاستعلام: 0.78s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    مصطلحات موضوعية: Breast cancer, Chemotherapy, Foot health, Podiatry, Quality of life

    Relation: https://doi.org/10.1186/s13047-023-00650-y; Veiga-Seijo R, Pertega-Diaz S, Perez-Lopez ME, Calvo Martinez L, Antolin Novoa S, Gonzalez-Martin C. Foot health and quality of life in women with breast cancer undergoing chemotherapy: a cross-sectional study. J Foot Ankle Res. 2023 Aug 21;16(1):52.; http://hdl.handle.net/2183/35013

  3. 3
    Academic Journal

    المساهمون: Institut Català de la Salut, Antolín Novoa S Breast Cancer Department, Hospital Universitario de A Coruña, La Coruña, Spain. Escrivá-de-Romaní Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Tolosa Ortega P Medical Oncology Department, Hospital Universitario 12 de Octubre, Spain. Oliva Fernández L Intercentre Clinical Management Unit of Integral Oncology of Málaga, Hospital Regional Universitario de Málaga, Málaga, Spain. Biomedical Research Institute of Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain. López López R Medical Oncology Dept. University Clinical Hospital and Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Centre for Biomedical Research in Networks on Cancer (CIBERONC), Madrid, Spain. López González A Department of Medical Oncology, Complejo asistencial Universitario de León. León, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Cancer Treatment and Research Communications;37; https://doi.org/10.1016/j.ctarc.2023.100772; Antolín Novoa S, Escrivá-de-Romaní S, Tolosa Ortega P, Oliva Fernández L, López López R, López González A, et al. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study). Cancer Treat Res Commun. 2023;37:100772.; https://hdl.handle.net/11351/10813

  4. 4
    Academic Journal
  5. 5
  6. 6
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
    Conference
  14. 14
    Conference
  15. 15
    Conference
  16. 16
    Conference
  17. 17
    Conference
  18. 18
    Conference
  19. 19
    Conference
  20. 20